As the half-lives of once-daily basal insulins have been prolonged, health care providershave learned both through clinical practice and real-world and clinical pharmacologystudies how to manage dosing in common clinical scenarios such as hypoglycemia,hospitalization, fasting (due to medical procedures, religious reasons, weight management)as well as exercise. The gene discussed is INS; the disease is Hypoglycemia.